-
2
-
-
70349578557
-
The diagnosis and management of monogenic diabetes in children and adolescents
-
supplement 12 2-s2.0-70349578557 10.1111/j.1399-5448.2009.00571.x
-
Hattersley A., Bruining J., Shield J., Njolstad P., Donaghue K. C., The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes 2009 10 supplement 12 33 42 2-s2.0-70349578557 10.1111/j.1399-5448.2009.00571.x
-
(2009)
Pediatric Diabetes
, vol.10
, pp. 33-42
-
-
Hattersley, A.1
Bruining, J.2
Shield, J.3
Njolstad, P.4
Donaghue, K.C.5
-
3
-
-
77953032291
-
Pharmacogenetics for type 2 diabetes: Practical considerations for study design
-
2-s2.0-77953032291
-
Vella A., Pharmacogenetics for type 2 diabetes: practical considerations for study design. Journal of Diabetes Science and Technology 2009 3 4 705 709 2-s2.0-77953032291
-
(2009)
Journal of Diabetes Science and Technology
, vol.3
, Issue.4
, pp. 705-709
-
-
Vella, A.1
-
4
-
-
77958172772
-
The effect of oral antidiabetic agents on A1C levels: A systematic review and meta-analysis
-
2-s2.0-77958172772 10.2337/dc09-1727
-
Sherifali D., Nerenberg K., Pullenayegum E., Cheng J. E., Gerstein H. C., The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010 33 8 1859 1864 2-s2.0-77958172772 10.2337/dc09-1727
-
(2010)
Diabetes Care
, vol.33
, Issue.8
, pp. 1859-1864
-
-
Sherifali, D.1
Nerenberg, K.2
Pullenayegum, E.3
Cheng, J.E.4
Gerstein, H.C.5
-
5
-
-
72849111539
-
Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: A go-DARTS study
-
2-s2.0-72849111539 10.1038/clpt.2009.176
-
Zhou K., Donnelly L., Burch L., Tavendale R., Doney A. S. F., Leese G., Hattersley A. T., McCarthy M. I., Morris A. D., Lang C. C., Palmer C. N. A., Pearson E. R., Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a go-DARTS study. Clinical Pharmacology and Therapeutics 2010 87 1 52 56 2-s2.0-72849111539 10.1038/clpt.2009.176
-
(2010)
Clinical Pharmacology and Therapeutics
, vol.87
, Issue.1
, pp. 52-56
-
-
Zhou, K.1
Donnelly, L.2
Burch, L.3
Tavendale, R.4
Doney, A.S.F.5
Leese, G.6
Hattersley, A.T.7
McCarthy, M.I.8
Morris, A.D.9
Lang, C.C.10
Palmer, C.N.A.11
Pearson, E.R.12
-
6
-
-
60449089649
-
Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
-
2-s2.0-60449089649 10.2337/dc08-9025
-
Nathan D. M., Buse J. B., Davidson M. B., Ferrannini E., Holman R. R., Sherwin R., Zinman B., Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009 32 1 193 203 2-s2.0-60449089649 10.2337/dc08-9025
-
(2009)
Diabetes Care
, vol.32
, Issue.1
, pp. 193-203
-
-
Nathan, D.M.1
Buse, J.B.2
Davidson, M.B.3
Ferrannini, E.4
Holman, R.R.5
Sherwin, R.6
Zinman, B.7
-
7
-
-
0036231580
-
Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers
-
DOI 10.1067/mcp.2002.122476
-
Kirchheiner J., Brockmöller J., Meineke I., Bauer S., Rohde W., Meisel C., Roots I., Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clinical Pharmacology and Therapeutics 2002 71 4 286 296 2-s2.0-0036231580 10.1067/mcp.2002.122476 (Pubitemid 34311458)
-
(2002)
Clinical Pharmacology and Therapeutics
, vol.71
, Issue.4
, pp. 286-296
-
-
Kirchheiner, J.1
Brockmoller, J.2
Meineke, I.3
Bauer, S.4
Rohde, W.5
Meisel, C.6
Roots, I.7
-
8
-
-
34548613766
-
Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination
-
DOI 10.1111/j.1365-2125.2007.02943.x
-
Elliot D. J., Suharjono S., Lewis B. C., Gillam E. M. J., Birkett D. J., Gross A. S., Miners J. O., Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination. British Journal of Clinical Pharmacology 2007 64 4 450 457 2-s2.0-34548613766 10.1111/j.1365-2125.2007.02943.x (Pubitemid 47404317)
-
(2007)
British Journal of Clinical Pharmacology
, vol.64
, Issue.4
, pp. 450-457
-
-
Elliot, D.J.1
Suharjono, S.2
Lewis, B.C.3
Gillam, E.M.J.4
Birkett, D.J.5
Gross, A.S.6
Miners, J.O.7
-
9
-
-
21844466772
-
Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms [2]
-
DOI 10.1016/j.clpt.2005.03.008, PII S0009923605001384
-
Wang R., Chen K., Wen S.-Y., Li J., Wang S.-Q., Pharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms. Clinical Pharmacology and Therapeutics 2005 78 1 90 92 2-s2.0-21844466772 10.1016/j.clpt.2005.03.008 (Pubitemid 40956936)
-
(2005)
Clinical Pharmacology and Therapeutics
, vol.78
, Issue.1
, pp. 90-92
-
-
Wang, R.1
Chen, K.2
Wen, S.-Y.3
Li, J.4
Wang, S.-Q.5
-
10
-
-
0036220552
-
Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers
-
DOI 10.1097/00008571-200203000-00004
-
Kirchheiner J., Bauer S., Meineke I., Rohde W., Prang V., Meisel C., Roots I., Brockmöller J., Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002 12 2 101 109 2-s2.0-0036220552 10.1097/00008571- 200203000-00004 (Pubitemid 34298914)
-
(2002)
Pharmacogenetics
, vol.12
, Issue.2
, pp. 101-109
-
-
Kirchheiner, J.1
Bauer, S.2
Meineke, I.3
Rohde, W.4
Prang, V.5
Meisel, C.6
Roots, I.7
Brockmoller, J.8
-
11
-
-
38349103468
-
Cytochrome P450 2C9 i2 and i3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus
-
2-s2.0-38349103468 10.1038/sj.clpt.6100273
-
Becker M. L., Visser L. E., Trienekens P. H., Hofman A., Van Schaik R. H. N., Stricker B. H. C., Cytochrome P450 2C9 i2 and i3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clinical Pharmacology and Therapeutics 2008 83 2 288 292 2-s2.0-38349103468 10.1038/sj.clpt.6100273
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.83
, Issue.2
, pp. 288-292
-
-
Becker, M.L.1
Visser, L.E.2
Trienekens, P.H.3
Hofman, A.4
Van Schaik, R.H.N.5
Stricker, B.H.C.6
-
12
-
-
78649710075
-
Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with type 2 diabetes mellitus
-
2-s2.0-78649710075 10.2217/pgs.10.121
-
Swen J. J., Wessels J. A. M., Krabben A., Assendelft W. J. J., Guchelaar H.-J., Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with type 2 diabetes mellitus. Pharmacogenomics 2010 11 11 1517 1523 2-s2.0-78649710075 10.2217/pgs.10.121
-
(2010)
Pharmacogenomics
, vol.11
, Issue.11
, pp. 1517-1523
-
-
Swen, J.J.1
Wessels, J.A.M.2
Krabben, A.3
Assendelft, W.J.J.4
Guchelaar, H.-J.5
-
13
-
-
1842505044
-
Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers
-
DOI 10.2165/00003088-200443040-00005
-
Kirchheiner J., Meineke I., Müller G., Bauer S., Rohde W., Meisel C., Roots I., Brockmöller J., Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers. Clinical Pharmacokinetics 2004 43 4 267 278 2-s2.0-1842505044 10.2165/00003088- 200443040-00005 (Pubitemid 38429306)
-
(2004)
Clinical Pharmacokinetics
, vol.43
, Issue.4
, pp. 267-278
-
-
Kirchheiner, J.1
Meineke, I.2
Muller, G.3
Bauer, S.4
Rohde, W.5
Meisel, C.6
Roots, I.7
Brockmoller, J.8
-
14
-
-
0042318871
-
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
-
DOI 10.1046/j.0306-5251.2003.01862.x
-
Bidstrup T. B., Bjørnsdottir I., Sidelmann U. G., Thomsen M. S., Hansen K. T., CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. British Journal of Clinical Pharmacology 2003 56 3 305 314 2-s2.0-0042318871 10.1046/j.0306-5251.2003.01862.x (Pubitemid 37059658)
-
(2003)
British Journal of Clinical Pharmacology
, vol.56
, Issue.3
, pp. 305-314
-
-
Bidstrup, T.B.1
Bjornsdottir, I.2
Sidelmann, U.G.3
Thomsen, M.S.4
Hansen, K.T.5
-
15
-
-
39149108768
-
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
-
DOI 10.1177/0091270007311569
-
Kalliokoski A., Neuvonen M., Neuvonen P. J., Niemi M., Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Journal of Clinical Pharmacology 2008 48 3 311 321 2-s2.0-39149108768 10.1177/0091270007311569 (Pubitemid 351257770)
-
(2008)
Journal of Clinical Pharmacology
, vol.48
, Issue.3
, pp. 311-321
-
-
Kalliokoski, A.1
Neuvonen, M.2
Neuvonen, P.J.3
Niemi, M.4
-
16
-
-
0030609143
-
Octameric stoichiometry of the K(ATP) channel complex
-
DOI 10.1085/jgp.110.6.655
-
Shyng S.-L., Nichols C. G., Octameric stoichiometry of the K(ATP) channel complex. Journal of General Physiology 1997 110 6 655 664 2-s2.0-0030609143 10.1085/jgp.110.6.655 (Pubitemid 27524606)
-
(1997)
Journal of General Physiology
, vol.110
, Issue.6
, pp. 655-664
-
-
Shyng, S.-L.1
Nichols, C.G.2
-
17
-
-
34547116194
-
Testing the bipartite model of the sulfonylurea receptor binding site: Binding of A-, B-, and a + B-site ligands
-
DOI 10.1124/jpet.107.123224
-
Winkler M., Stephan D., Bieger S., Kühner P., Wolff F., Quast U., Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and a + B-site ligands. Journal of Pharmacology and Experimental Therapeutics 2007 322 2 701 708 2-s2.0-34547116194 10.1124/jpet.107.123224 (Pubitemid 47105784)
-
(2007)
Journal of Pharmacology and Experimental Therapeutics
, vol.322
, Issue.2
, pp. 701-708
-
-
Winkler, M.1
Stephan, D.2
Bieger, S.3
Kuhner, P.4
Wolff, F.5
Quast, U.6
-
18
-
-
70349648967
-
Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+ channel
-
2-s2.0-70349648967 10.2337/db09-0143
-
Hamming K. S. C., Soliman D., Matemisz L. C., Niazi O., Lang Y., Gloyn A. L., Light P. E., Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+ channel. Diabetes 2009 58 10 2419 2424 2-s2.0-70349648967 10.2337/db09-0143
-
(2009)
Diabetes
, vol.58
, Issue.10
, pp. 2419-2424
-
-
Hamming, K.S.C.1
Soliman, D.2
Matemisz, L.C.3
Niazi, O.4
Lang, Y.5
Gloyn, A.L.6
Light, P.E.7
-
19
-
-
85027917672
-
Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A
-
2-s2.0-84855176516 10.1097/FPC.0b013e32835001e7
-
Lang V. Y., Fatehi M., Light P. E., Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenetics and Genomics 2012 22 3 206 214 2-s2.0-84855176516 10.1097/FPC.0b013e32835001e7
-
(2012)
Pharmacogenetics and Genomics
, vol.22
, Issue.3
, pp. 206-214
-
-
Lang, V.Y.1
Fatehi, M.2
Light, P.E.3
-
20
-
-
33746686369
-
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
-
DOI 10.1056/NEJMoa061759
-
Pearson E. R., Flechtner I., Njølstad P. R., Malecki M. T., Flanagan S. E., Larkin B., Ashcroft F. M., Klimes I., Codner E., Iotova V., Slingerland A. S., Shield J., Robert J.-J., Holst J. J., Clark P. M., Ellard S., Søvik O., Polak M., Hattersley A. T., Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. The New England Journal of Medicine 2006 355 5 467 477 2-s2.0-33746686369 10.1056/NEJMoa061759 (Pubitemid 44162274)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.5
, pp. 467-477
-
-
Pearson, E.R.1
Flechtner, I.2
Njolstad, P.R.3
Malecki, M.T.4
Flanagan, S.E.5
Larkin, B.6
Ashcroft, F.M.7
Klimes, I.8
Codner, E.9
Iotova, V.10
Slingerland, A.S.11
Shield, J.12
Robert, J.-J.13
Holst, J.J.14
Clark, P.M.15
Ellard, S.16
Sovik, O.17
Polak, M.18
Hattersley, A.T.19
-
21
-
-
38949177444
-
Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations
-
DOI 10.2337/dc07-1785
-
Rafiq M., Flanagan S. E., Patch A.-M., Shields B. M., Ellard S., Hattersley A. T., Batra C., Bruining J., Carson D., Codner E., Cummings E., Curran J., Davis E., Deiss D., Herr M., Hussain K., Legault L., Malecki M., Paskova M., Pearson E., Rodda C., Rothenbuhler A., Sanchez J., Shield J., Stanca R.-M., Van Der Meulen J., Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008 31 2 204 209 2-s2.0-38949177444 10.2337/dc07-1785 (Pubitemid 351213320)
-
(2008)
Diabetes Care
, vol.31
, Issue.2
, pp. 204-209
-
-
Rafiq, M.1
Flanagan, S.E.2
Patch, A.-M.3
Shields, B.M.4
Ellard, S.5
Hattersley, A.T.6
Batra, C.7
Bruining, J.8
Carson, D.9
Codner, E.10
Cummings, E.11
Curran, J.12
Davis, E.13
Deiss, D.14
Herr, M.15
Hussain, K.16
Legault, L.17
Malecki, M.18
Paskova, M.19
Pearson, E.20
Rodda, C.21
Rothenbuhler, A.22
Sanchez, J.23
Shield, J.24
Stanca, R.-M.25
Van Der Meulen, J.26
more..
-
22
-
-
2342561802
-
Haplotype Structure and Genotype-Phenotype Correlations of the Sulfonylurea Receptor and the Islet ATP-Sensitive Potassium Channel Gene Region
-
DOI 10.2337/diabetes.53.5.1360
-
Florez J. C., Burtt N., de Bakker P. I. W., Almgren P., Tuomi T., Holmkvist J., Gaudet D., Hudson T. J., Schaffner S. F., Daly M. J., Hirschhorn J. N., Groop L., Altshuler D., Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes 2004 53 5 1360 1368 2-s2.0-2342561802 10.2337/diabetes.53.5.1360 (Pubitemid 38569024)
-
(2004)
Diabetes
, vol.53
, Issue.5
, pp. 1360-1368
-
-
Florez, J.C.1
Burtt, N.2
De Bakker, P.I.W.3
Almgren, P.4
Tuomi, T.5
Holmkvist, J.6
Gaudet, D.7
Hudson, T.J.8
Schaffner, S.F.9
Daly, M.J.10
Hirschhorn, J.N.11
Groop, L.12
Altshuler, D.13
-
23
-
-
56149106823
-
Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients
-
2-s2.0-56149106823 10.2337/dc07-2248
-
Feng Y., Mao G., Ren X., Xing H., Tang G., Li Q., Li X., Sun L., Yang J., Ma W., Wang X., Xu X., Ser 1369Ala variant in sulfonylurea receptor gene ABCC8 Is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care 2008 31 10 1939 1944 2-s2.0-56149106823 10.2337/dc07-2248
-
(2008)
Diabetes Care
, vol.31
, Issue.10
, pp. 1939-1944
-
-
Feng, Y.1
Mao, G.2
Ren, X.3
Xing, H.4
Tang, G.5
Li, Q.6
Li, X.7
Sun, L.8
Yang, J.9
Ma, W.10
Wang, X.11
Xu, X.12
-
24
-
-
34247144968
-
Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes
-
DOI 10.1016/j.diabres.2006.10.021, PII S016882270600492X
-
Zhang H., Liu X., Kuang H., Yi R., Xing H., Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Research and Clinical Practice 2007 77 1 58 61 2-s2.0-34247144968 10.1016/j.diabres.2006.10.021 (Pubitemid 46590477)
-
(2007)
Diabetes Research and Clinical Practice
, vol.77
, Issue.1
, pp. 58-61
-
-
Zhang, H.1
Liu, X.2
Kuang, H.3
Yi, R.4
Xing, H.5
-
25
-
-
84858749051
-
KCNJ11 gene E23K variant and therapeutic response to sulfonylureas
-
2-s2.0-84858749051 10.1016/j.ejim.2011.10.018
-
Javorsky M., Klimcakova L., Schroner Z., Zidzik J., Babjakova E., Fabianova M., Kozarova M., Tkacova R., Salagovic J., Tkac I., KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. European Journal of Internal Medicine 2012 23 3 245 249 2-s2.0-84858749051 10.1016/j.ejim.2011.10.018
-
(2012)
European Journal of Internal Medicine
, vol.23
, Issue.3
, pp. 245-249
-
-
Javorsky, M.1
Klimcakova, L.2
Schroner, Z.3
Zidzik, J.4
Babjakova, E.5
Fabianova, M.6
Kozarova, M.7
Tkacova, R.8
Salagovic, J.9
Tkac, I.10
-
26
-
-
0035043009
-
Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)
-
DOI 10.1046/j.1464-5491.2001.00449.x
-
Gloyn A. L., Hashim Y., Ashcroft S. J. H., Ashfield R., Wiltshire S., Turner R. C., Association studies of variants in promoter and coding regions of beta-cell ATP sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). Diabetic Medicine 2001 18 3 206 212 2-s2.0-0037349226 10.1046/j.1464-5491.2003.00944.x (Pubitemid 32397858)
-
(2001)
Diabetic Medicine
, vol.18
, Issue.3
, pp. 206-212
-
-
Gloyn, A.L.1
Hashim, Y.2
Ashcroft, S.J.H.3
Ashfield, R.4
Wiltshire, S.5
Turner, R.C.6
-
27
-
-
33744965950
-
The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes
-
DOI 10.1210/jc.2005-2323
-
Sesti G., Laratta E., Cardellini M., Andreozzi F., Del Guerra S., Irace C., Gnasso A., Grupillo M., Lauro R., Hribal M. L., Perticone F., Marchetti P., The E23K variant of KCNJ11 encoding the pancreatic β -cell adenosine 5′-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2006 91 6 2334 2339 2-s2.0-33744965950 10.1210/jc.2005-2323 (Pubitemid 43855025)
-
(2006)
Journal of Clinical Endocrinology and Metabolism
, vol.91
, Issue.6
, pp. 2334-2339
-
-
Sesti, G.1
Laratta, E.2
Cardellini, M.3
Andreozzi, F.4
Del Guerra, S.5
Irace, C.6
Gnasso, A.7
Grupillo, M.8
Lauro, R.9
Hribal, M.L.10
Perticone, F.11
Marchetti, P.12
-
28
-
-
49249118751
-
Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients
-
2-s2.0-49249118751 10.1111/j.1745-7254.2008.00840.x
-
He Y.-Y., Zhang R., Shao X.-Y., Hu C., Wang C.-R., Lu J.-X., Bao Y.-Q., Jia W.-P., Xiang K.-S., Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacologica Sinica 2008 29 8 983 989 2-s2.0-49249118751 10.1111/j.1745-7254.2008.00840.x
-
(2008)
Acta Pharmacologica Sinica
, vol.29
, Issue.8
, pp. 983-989
-
-
He, Y.-Y.1
Zhang, R.2
Shao, X.-Y.3
Hu, C.4
Wang, C.-R.5
Lu, J.-X.6
Bao, Y.-Q.7
Jia, W.-P.8
Xiang, K.-S.9
-
29
-
-
32544451924
-
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
-
2-s2.0-32544451924 10.1038/ng1732
-
Grant S. F. A., Thorleifsson G., Reynisdottir I., Benediktsson R., Manolescu A., Sainz J., Helgason A., Stefansson H., Emilsson V., Helgadottir A., Styrkarsdottir U., Magnusson K. P., Walters G. B., Palsdottir E., Jonsdottir T., Gudmundsdottir T., Gylfason A., Saemundsdottir J., Wilensky R. L., Reilly M. P., Rader D. J., Bagger Y., Christiansen C., Gudnason V., Sigurdsson G., Thorsteinsdottir U., Gulcher J. R., Kong A., Stefansson K., Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nature Genetics 2006 38 3 320 323 2-s2.0-32544451924 10.1038/ng1732
-
(2006)
Nature Genetics
, vol.38
, Issue.3
, pp. 320-323
-
-
Grant, S.F.A.1
Thorleifsson, G.2
Reynisdottir, I.3
Benediktsson, R.4
Manolescu, A.5
Sainz, J.6
Helgason, A.7
Stefansson, H.8
Emilsson, V.9
Helgadottir, A.10
Styrkarsdottir, U.11
Magnusson, K.P.12
Walters, G.B.13
Palsdottir, E.14
Jonsdottir, T.15
Gudmundsdottir, T.16
Gylfason, A.17
Saemundsdottir, J.18
Wilensky, R.L.19
Reilly, M.P.20
Rader, D.J.21
Bagger, Y.22
Christiansen, C.23
Gudnason, V.24
Sigurdsson, G.25
Thorsteinsdottir, U.26
Gulcher, J.R.27
Kong, A.28
Stefansson, K.29
more..
-
30
-
-
61849101938
-
Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: A large Human Genome Epidemiology (HuGE) review and meta-analysis
-
2-s2.0-61849101938 10.1186/1471-2350-10-15
-
Tong Y., Lin Y., Zhang Y., Yang J., Zhang Y., Liu H., Zhang B., Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Medical Genetics 2009 10, article 15 2-s2.0-61849101938 10.1186/1471-2350-10-15
-
(2009)
BMC Medical Genetics
, vol.1015
-
-
Tong, Y.1
Lin, Y.2
Zhang, Y.3
Yang, J.4
Zhang, Y.5
Liu, H.6
Zhang, B.7
-
31
-
-
12544254474
-
TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β -catenin and glycogen synthase kinase-3 β
-
2-s2.0-12544254474 10.1074/jbc.M411487200
-
Yi F., Brubaker P. L., Jin T., TCF-4 mediates cell type-specific regulation of proglucagon gene expression by β -catenin and glycogen synthase kinase-3 β The Journal of Biological Chemistry 2005 280 2 1457 1464 2-s2.0-12544254474 10.1074/jbc.M411487200
-
(2005)
The Journal of Biological Chemistry
, vol.280
, Issue.2
, pp. 1457-1464
-
-
Yi, F.1
Brubaker, P.L.2
Jin, T.3
-
32
-
-
33746075560
-
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program
-
DOI 10.1056/NEJMoa062418
-
Florez J. C., Jablonski K. A., Bayley N., Pollin T. I., De Bakker P. I. W., Shuldiner A. R., Knowler W. C., Nathan D. M., Altshuler D., TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. The New England Journal of Medicine 2006 355 3 241 250 2-s2.0-33746075560 10.1056/NEJMoa062418 (Pubitemid 44079339)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.3
, pp. 241-250
-
-
Florez, J.C.1
Jablonski, K.A.2
Bayley, N.3
Pollin, T.I.4
De Bakker, P.I.W.5
Shuldiner, A.R.6
Knowler, W.C.7
Nathan, D.M.8
Altshuler, D.9
-
33
-
-
33750892139
-
Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals
-
DOI 10.2337/db06-0381
-
Saxena R., Gianniny L., Burtt N. P., Lyssenko V., Giuducci C., Sjögren M., Florez J. C., Almgren P., Isomaa B., Orho-Melander M., Lindblad U., Daly M. J., Tuomi T., Hirschhorn J. N., Ardlie K. G., Groop L. C., Altshuler D., Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes 2006 55 10 2890 2895 2-s2.0-33750892139 10.2337/db06-0381 (Pubitemid 44923692)
-
(2006)
Diabetes
, vol.55
, Issue.10
, pp. 2890-2895
-
-
Saxena, R.1
Gianniny, L.2
Burtt, N.P.3
Lyssenko, V.4
Giuducci, C.5
Sjogren, M.6
Florez, J.C.7
Almgren, P.8
Isomaa, B.9
Orho-Melander, M.10
Lindblad, U.11
Daly, M.J.12
Tuomi, T.13
Hirschhorn, J.N.14
Ardlie, K.G.15
Groop, L.C.16
Altshuler, D.17
-
34
-
-
67349270566
-
Translating TCF7L2: From gene to function
-
2-s2.0-67349270566 10.1007/s00125-009-1356-1
-
Pearson E. R., Translating TCF7L2: from gene to function. Diabetologia 2009 52 7 1227 1230 2-s2.0-67349270566 10.1007/s00125-009-1356-1
-
(2009)
Diabetologia
, vol.52
, Issue.7
, pp. 1227-1230
-
-
Pearson, E.R.1
-
35
-
-
77449099615
-
TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action
-
2-s2.0-77449099615 10.2337/db09-1169
-
Villareal D. T., Robertson H., Bell G. I., Patterson B. W., Tran H., Wice B., Polonsky K. S., TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010 59 2 479 485 2-s2.0-77449099615 10.2337/db09-1169
-
(2010)
Diabetes
, vol.59
, Issue.2
, pp. 479-485
-
-
Villareal, D.T.1
Robertson, H.2
Bell, G.I.3
Patterson, B.W.4
Tran, H.5
Wice, B.6
Polonsky, K.S.7
-
36
-
-
34547585382
-
Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study
-
DOI 10.2337/db07-0440
-
Pearson E. R., Donnelly L. A., Kimber C., Whitley A., Doney A. S. F., McCarthy M. I., Hattersley A. T., Morris A. D., Palmer C. N. A., Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs Study. Diabetes 2007 56 8 2178 2182 2-s2.0-34547585382 10.2337/db07-0440 (Pubitemid 47195841)
-
(2007)
Diabetes
, vol.56
, Issue.8
, pp. 2178-2182
-
-
Pearson, E.R.1
Donnelly, L.A.2
Kimber, C.3
Whitley, A.4
Doney, A.S.F.5
McCarthy, M.I.6
Hattersley, A.T.7
Morris, A.D.8
Palmer, C.N.A.9
-
37
-
-
84874894776
-
Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide
-
374858 10.1155/2013/374858
-
Javorský M., Babjaková E., Klimčáková L., Association between TCF7L2 genotype and glycemic control in diabetic patients treated with gliclazide. International Journal of Endocrinology 2013 2013 5 374858 10.1155/2013/374858
-
(2013)
International Journal of Endocrinology
, vol.2013
, pp. 5
-
-
Javorský, M.1
Babjaková, E.2
Klimčáková, L.3
-
38
-
-
79951960556
-
TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes
-
2-s2.0-79951960556 10.1186/1471-2350-12-30
-
Holstein A., Hahn M., Körner A., Stumvoll M., Kovacs P., TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Medical Genetics 2011 12, article 30 2-s2.0-79951960556 10.1186/1471-2350-12-30
-
(2011)
BMC Medical Genetics
, vol.1230
-
-
Holstein, A.1
Hahn, M.2
Körner, A.3
Stumvoll, M.4
Kovacs, P.5
-
39
-
-
78751500357
-
Clinical pharmacokinetics of metformin
-
2-s2.0-78751500357 10.2165/11534750-000000000-00000
-
Graham G. G., Punt J., Arora M., Day R. O., Doogue M. P., Duong J. K., Furlong T. J., Greenfield J. R., Greenup L. C., Kirkpatrick C. M., Ray J. E., Timmins P., Williams K. M., Clinical pharmacokinetics of metformin. Clinical Pharmacokinetics 2011 50 2 81 98 2-s2.0-78751500357 10.2165/11534750-000000000- 00000
-
(2011)
Clinical Pharmacokinetics
, vol.50
, Issue.2
, pp. 81-98
-
-
Graham, G.G.1
Punt, J.2
Arora, M.3
Day, R.O.4
Doogue, M.P.5
Duong, J.K.6
Furlong, T.J.7
Greenfield, J.R.8
Greenup, L.C.9
Kirkpatrick, C.M.10
Ray, J.E.11
Timmins, P.12
Williams, K.M.13
-
40
-
-
79251612707
-
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
-
2-s2.0-79251612707 10.1038/ng.735
-
Zhou K., Bellenguez C., Spencer C. C. A., Bennett A. J., Coleman R. L., Tavendale R., Hawley S. A., Donnelly L. A., Schofield C., Groves C. J., Burch L., Carr F., Strange A., Freeman C., Blackwell J. M., Bramon E., Brown M. A., Casas J. P., Corvin A., Craddock N., Deloukas P., Dronov S., Duncanson A., Edkins S., Gray E., Hunt S., Jankowski J., Langford C., Markus H. S., Mathew C. G., Plomin R., Rautanen A., Sawcer S. J., Samani N. J., Trembath R., Viswanathan A. C., Wood N. W., Harries L. W., Hattersley A. T., Doney A. S. F., Colhoun H., Morris A. D., Sutherland C., Hardie D. G., Peltonen L., McCarthy M. I., Holman R. R., Palmer C. N. A., Donnelly P., Pearson E. R., Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics 2011 43 2 117 120 2-s2.0-79251612707 10.1038/ng.735
-
(2011)
Nature Genetics
, vol.43
, Issue.2
, pp. 117-120
-
-
Zhou, K.1
Bellenguez, C.2
Spencer, C.C.A.3
Bennett, A.J.4
Coleman, R.L.5
Tavendale, R.6
Hawley, S.A.7
Donnelly, L.A.8
Schofield, C.9
Groves, C.J.10
Burch, L.11
Carr, F.12
Strange, A.13
Freeman, C.14
Blackwell, J.M.15
Bramon, E.16
Brown, M.A.17
Casas, J.P.18
Corvin, A.19
Craddock, N.20
Deloukas, P.21
Dronov, S.22
Duncanson, A.23
Edkins, S.24
Gray, E.25
Hunt, S.26
Jankowski, J.27
Langford, C.28
Markus, H.S.29
Mathew, C.G.30
Plomin, R.31
Rautanen, A.32
Sawcer, S.J.33
Samani, N.J.34
Trembath, R.35
Viswanathan, A.C.36
Wood, N.W.37
Harries, L.W.38
Hattersley, A.T.39
Doney, A.S.F.40
Colhoun, H.41
Morris, A.D.42
Sutherland, C.43
Hardie, D.G.44
Peltonen, L.45
McCarthy, M.I.46
Holman, R.R.47
Palmer, C.N.A.48
Donnelly, P.49
Pearson, E.R.50
more..
-
41
-
-
84866319096
-
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: A replication and meta-analysis of five cohorts
-
2-s2.0-84858714611 10.1007/s00125-012-2537-x
-
van Leeuwen N., Nijpels G., Becker M. L., Deshmukh H., Zhou K., Stricker B. H. C., Uitterlinden A. G., Hofman A., van 't Riet E., Palmer C. N. A., Guigas B., Slagboom P. E., Durrington P., Calle R. A., Neil A., Hitman G., Livingstone S. J., Colhoun H., Holman R. R., McCarthy M. I., Dekker J. M., 't Hart L. M., Pearson E. R., A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia 2012 55 7 1971 1977 2-s2.0-84858714611 10.1007/s00125-012-2537-x
-
(2012)
Diabetologia
, vol.55
, Issue.7
, pp. 1971-1977
-
-
Van Leeuwen, N.1
Nijpels, G.2
Becker, M.L.3
Deshmukh, H.4
Zhou, K.5
Stricker, B.H.C.6
Uitterlinden, A.G.7
Hofman, A.8
Van 'T Riet, E.9
Palmer, C.N.A.10
Guigas, B.11
Slagboom, P.E.12
Durrington, P.13
Calle, R.A.14
Neil, A.15
Hitman, G.16
Livingstone, S.J.17
Colhoun, H.18
Holman, R.R.19
McCarthy, M.I.20
Dekker, J.M.21
'T Hart, L.M.22
Pearson, E.R.23
more..
-
42
-
-
84865457823
-
The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program
-
Florez J. C., Jablonski K. A., Taylor A., The C allele of ATM rs11212617 does not associate with metformin response in the Diabetes Prevention Program. Diabetes Care 2012 35 9 1864 1867
-
(2012)
Diabetes Care
, vol.35
, Issue.9
, pp. 1864-1867
-
-
Florez, J.C.1
Jablonski, K.A.2
Taylor, A.3
-
43
-
-
34248156160
-
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
-
DOI 10.1172/JCI30558
-
Shu Y., Sheardown S. A., Brown C., Owen R. P., Zhang S., Castro R. A., Ianculescu A. G., Yue L., Lo J. C., Burchard E. G., Brett C. M., Giacomini K. M., Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. The Journal of Clinical Investigation 2007 117 5 1422 1431 2-s2.0-34248156160 10.1172/JCI30558 (Pubitemid 46718430)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.5
, pp. 1422-1431
-
-
Shu, Y.1
Sheardown, S.A.2
Brown, C.3
Owen, R.P.4
Zhang, S.5
Castro, R.A.6
Ianculescu, A.G.7
Yue, L.8
Lo, J.C.9
Burchard, E.G.10
Brett, C.M.11
Giacomini, K.M.12
-
44
-
-
38349085099
-
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics
-
2-s2.0-38349085099 10.1038/sj.clpt.6100275
-
Shu Y., Brown C., Castro R. A., Shi R. J., Lin E. T., Owen R. P., Sheardown S. A., Yue L., Burchard E. G., Brett C. M., Giacomini K. M., Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clinical Pharmacology and Therapeutics 2008 83 2 273 280 2-s2.0-38349085099 10.1038/sj.clpt.6100275
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.83
, Issue.2
, pp. 273-280
-
-
Shu, Y.1
Brown, C.2
Castro, R.A.3
Shi, R.J.4
Lin, E.T.5
Owen, R.P.6
Sheardown, S.A.7
Yue, L.8
Burchard, E.G.9
Brett, C.M.10
Giacomini, K.M.11
-
45
-
-
44949087480
-
Polymorphism in human organic cation transporters and metformin action
-
DOI 10.2217/14622416.9.4.415
-
Takane H., Shikata E., Otsubo K., Higuchi S., Ieiri I., Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008 9 4 415 422 2-s2.0-44949087480 10.2217/14622416.9.4.415 (Pubitemid 351803926)
-
(2008)
Pharmacogenomics
, vol.9
, Issue.4
, pp. 415-422
-
-
Takane, H.1
Shikata, E.2
Otsubo, K.3
Higuchi, S.4
Ieiri, I.5
-
46
-
-
70350075408
-
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver
-
2-s2.0-70350075408 10.1002/hep.23103
-
Nies A. T., Koepsell H., Winter S., Burk O., Klein K., Kerb R., Zanger U. M., Keppler D., Schwab M., Schaeffeler E., Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 2009 50 4 1227 1240 2-s2.0-70350075408 10.1002/hep.23103
-
(2009)
Hepatology
, vol.50
, Issue.4
, pp. 1227-1240
-
-
Nies, A.T.1
Koepsell, H.2
Winter, S.3
Burk, O.4
Klein, K.5
Kerb, R.6
Zanger, U.M.7
Keppler, D.8
Schwab, M.9
Schaeffeler, E.10
-
47
-
-
69449098951
-
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin
-
2-s2.0-69449098951 10.1038/clpt.2009.92
-
Tzvetkov M. V., Vormfelde S. V., Balen D., Meineke I., Schmidt T., Sehrt D., Sabolić I., Koepsell H., Brockmöller J., The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clinical Pharmacology and Therapeutics 2009 86 3 299 306 2-s2.0-69449098951 10.1038/clpt.2009.92
-
(2009)
Clinical Pharmacology and Therapeutics
, vol.86
, Issue.3
, pp. 299-306
-
-
Tzvetkov, M.V.1
Vormfelde, S.V.2
Balen, D.3
Meineke, I.4
Schmidt, T.5
Sehrt, D.6
Sabolić, I.7
Koepsell, H.8
Brockmöller, J.9
-
48
-
-
66649121405
-
Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study
-
2-s2.0-66649121405 10.2337/db08-0896
-
Zhou K., Donnelly L. A., Kimber C. H., Donnan P. T., Doney A. S. F., Leese G., Hattersley A. T., McCarthy M. I., Morris A. D., Palmer C. N. A., Pearson E. R., Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes 2009 58 6 1434 1439 2-s2.0-66649121405 10.2337/db08-0896
-
(2009)
Diabetes
, vol.58
, Issue.6
, pp. 1434-1439
-
-
Zhou, K.1
Donnelly, L.A.2
Kimber, C.H.3
Donnan, P.T.4
Doney, A.S.F.5
Leese, G.6
Hattersley, A.T.7
McCarthy, M.I.8
Morris, A.D.9
Palmer, C.N.A.10
Pearson, E.R.11
-
49
-
-
81055140250
-
The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c
-
2-s2.0-81055140250 10.1097/FPC.0b013e32834c0010
-
Christensen M. M. H., Brasch-Andersen C., Green H., Nielsen F., Damkier P., Beck-Nielsen H., Brosen K., The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics 2011 21 12 837 850 2-s2.0-81055140250 10.1097/FPC.0b013e32834c0010
-
(2011)
Pharmacogenetics and Genomics
, vol.21
, Issue.12
, pp. 837-850
-
-
Christensen, M.M.H.1
Brasch-Andersen, C.2
Green, H.3
Nielsen, F.4
Damkier, P.5
Beck-Nielsen, H.6
Brosen, K.7
-
50
-
-
67849116869
-
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
-
2-s2.0-67849116869 10.1038/tpj.2009.15
-
Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics Journal 2009 9 4 242 247 2-s2.0-67849116869 10.1038/tpj.2009.15
-
(2009)
Pharmacogenomics Journal
, vol.9
, Issue.4
, pp. 242-247
-
-
Becker, M.L.1
Visser, L.E.2
Van Schaik, R.H.N.3
Hofman, A.4
Uitterlinden, A.G.5
Stricker, B.H.C.6
-
51
-
-
84864950319
-
Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients
-
Tarasova L., Kalnina I., Geldnere K., Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenetics and Genomics 2012 22 9 659 666
-
(2012)
Pharmacogenetics and Genomics
, vol.22
, Issue.9
, pp. 659-666
-
-
Tarasova, L.1
Kalnina, I.2
Geldnere, K.3
-
52
-
-
76949107912
-
SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin
-
2-s2.0-76949107912 10.1038/aps.2009.189
-
Li Q., Liu F., Zheng T.-S., Tang J.-L., Lu H.-J., Jia W.-P., SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacologica Sinica 2010 31 2 184 190 2-s2.0-76949107912 10.1038/aps.2009.189
-
(2010)
Acta Pharmacologica Sinica
, vol.31
, Issue.2
, pp. 184-190
-
-
Li, Q.1
Liu, F.2
Zheng, T.-S.3
Tang, J.-L.4
Lu, H.-J.5
Jia, W.-P.6
-
53
-
-
54249106729
-
Genetic variants of the organic cation transporter 2 influence the disposition of metformin
-
2-s2.0-54249106729 10.1038/clpt.2008.61
-
Song I. S., Shin H. J., Shim E. J., Jung I. S., Kim W. Y., Shon J. H., Shin J. G., Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clinical Pharmacology and Therapeutics 2008 84 5 559 562 2-s2.0-54249106729 10.1038/clpt.2008.61
-
(2008)
Clinical Pharmacology and Therapeutics
, vol.84
, Issue.5
, pp. 559-562
-
-
Song, I.S.1
Shin, H.J.2
Shim, E.J.3
Jung, I.S.4
Kim, W.Y.5
Shon, J.H.6
Shin, J.G.7
-
54
-
-
53049095113
-
OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine
-
2-s2.0-53049095113 10.1097/FPC.0b013e328302cd41
-
Wang Z.-J., Yin O. Q. P., Tomlinson B., Chow M. S. S., OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenetics and Genomics 2008 18 7 637 645 2-s2.0-53049095113 10.1097/FPC.0b013e328302cd41
-
(2008)
Pharmacogenetics and Genomics
, vol.18
, Issue.7
, pp. 637-645
-
-
Wang, Z.-J.1
Yin, O.Q.P.2
Tomlinson, B.3
Chow, M.S.S.4
-
55
-
-
67651235787
-
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin
-
2-s2.0-67651235787 10.1097/FPC.0b013e32832cc7e9
-
Chen Y., Li S., Brown C., Cheatham S., Castro R. A., Leabman M. K., Urban T. J., Chen L., Yee S. W., Choi J. H., Huang Y., Brett C. M., Burchard E. G., Giacomini K. M., Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenetics and Genomics 2009 19 7 497 504 2-s2.0-67651235787 10.1097/FPC.0b013e32832cc7e9
-
(2009)
Pharmacogenetics and Genomics
, vol.19
, Issue.7
, pp. 497-504
-
-
Chen, Y.1
Li, S.2
Brown, C.3
Cheatham, S.4
Castro, R.A.5
Leabman, M.K.6
Urban, T.J.7
Chen, L.8
Yee, S.W.9
Choi, J.H.10
Huang, Y.11
Brett, C.M.12
Burchard, E.G.13
Giacomini, K.M.14
-
56
-
-
62749133967
-
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study
-
2-s2.0-62749133967 10.2337/db08-1028
-
Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study. Diabetes 2009 58 3 745 749 2-s2.0-62749133967 10.2337/db08-1028
-
(2009)
Diabetes
, vol.58
, Issue.3
, pp. 745-749
-
-
Becker, M.L.1
Visser, L.E.2
Van Schaik, R.H.N.3
Hofman, A.4
Uitterlinden, A.G.5
Stricker, B.H.C.6
-
57
-
-
73949087018
-
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response
-
2-s2.0-73949087018 10.1097/FPC.0b013e328333bb11
-
Becker M. L., Visser L. E., van Schaik R. H. N., Hofman A., Uitterlinden A. G., Stricker B. H. C., Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenetics and Genomics 2010 20 1 38 44 2-s2.0-73949087018 10.1097/FPC.0b013e328333bb11
-
(2010)
Pharmacogenetics and Genomics
, vol.20
, Issue.1
, pp. 38-44
-
-
Becker, M.L.1
Visser, L.E.2
Van Schaik, R.H.N.3
Hofman, A.4
Uitterlinden, A.G.5
Stricker, B.H.C.6
-
58
-
-
77957601724
-
Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program
-
2-s2.0-77957601724 10.2337/db10-0543
-
Jablonski K. A., McAteer J. B., de Bakker P. I. W., Franks P. W., Pollin T. I., Hanson R. L., Saxena R., Fowler S., Shuldiner A. R., Knowler W. C., Altshuler D., Florez J. C., Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes 2010 59 10 2672 2681 2-s2.0-77957601724 10.2337/db10-0543
-
(2010)
Diabetes
, vol.59
, Issue.10
, pp. 2672-2681
-
-
Jablonski, K.A.1
McAteer, J.B.2
De Bakker, P.I.W.3
Franks, P.W.4
Pollin, T.I.5
Hanson, R.L.6
Saxena, R.7
Fowler, S.8
Shuldiner, A.R.9
Knowler, W.C.10
Altshuler, D.11
Florez, J.C.12
-
59
-
-
84871937263
-
Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes
-
Tkáč I., Klimčáková L., Javorský M., Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes. Diabetes Obesity and Metabolism 2012 15 2 189 191
-
(2012)
Diabetes Obesity and Metabolism
, vol.15
, Issue.2
, pp. 189-191
-
-
Tkáč, I.1
Klimčáková, L.2
Javorský, M.3
-
60
-
-
84872679649
-
The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin
-
Stocker S. L., Morrissey K. M., Yee S. W., The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin. Clinical Pharmacology and Therapeutics 2013 93 2 186 194
-
(2013)
Clinical Pharmacology and Therapeutics
, vol.93
, Issue.2
, pp. 186-194
-
-
Stocker, S.L.1
Morrissey, K.M.2
Yee, S.W.3
-
61
-
-
80054970528
-
A common 5′-UTR variant in MATE2-K is associated with poor response to metformin
-
2-s2.0-80054970528 10.1038/clpt.2011.165
-
Choi J. H., Yee S. W., Ramirez A. H., Morrissey K. M., Jang G. H., Joski P. J., Mefford J. A., Hesselson S. E., Schlessinger A., Jenkins G., Castro R. A., Johns S. J., Stryke D., Sali A., Ferrin T. E., Witte J. S., Kwok P.-Y., Roden D. M., Wilke R. A., McCarty C. A., Davis R. L., Giacomini K. M., A common 5′-UTR variant in MATE2-K is associated with poor response to metformin. Clinical Pharmacology and Therapeutics 2011 90 5 674 684 2-s2.0-80054970528 10.1038/clpt.2011.165
-
(2011)
Clinical Pharmacology and Therapeutics
, vol.90
, Issue.5
, pp. 674-684
-
-
Choi, J.H.1
Yee, S.W.2
Ramirez, A.H.3
Morrissey, K.M.4
Jang, G.H.5
Joski, P.J.6
Mefford, J.A.7
Hesselson, S.E.8
Schlessinger, A.9
Jenkins, G.10
Castro, R.A.11
Johns, S.J.12
Stryke, D.13
Sali, A.14
Ferrin, T.E.15
Witte, J.S.16
Kwok, P.-Y.17
Roden, D.M.18
Wilke, R.A.19
McCarty, C.A.20
Davis, R.L.21
Giacomini, K.M.22
more..
-
62
-
-
33845515897
-
Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype
-
DOI 10.1016/j.clpt.2006.09.008, PII S0009923606003869
-
Kirchheiner J., Thomas S., Bauer S., Tomalik-Scharte D., Hering U., Doroshyenko O., Jetter A., Stehle S., Tsahuridu M., Meineke I., Brockmöller J., Fuhr U., Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clinical Pharmacology and Therapeutics 2006 80 6 657 667 2-s2.0-33845515897 10.1016/j.clpt.2006.09.008 (Pubitemid 44920222)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.80
, Issue.6
, pp. 657-667
-
-
Kirchheiner, J.1
Thomas, S.2
Bauer, S.3
Tomalik-Scharte, D.4
Hering, U.5
Doroshyenko, O.6
Jetter, A.7
Stehle, S.8
Tsahuridu, M.9
Meineke, I.10
Brockmoller, J.11
Fuhr, U.12
-
63
-
-
37549040583
-
Trimethoprim and the CYP2C8i3 allele have opposite effects on the pharmacokinetics of pioglitazone
-
2-s2.0-37549040583 10.1124/dmd.107.018010
-
Tornio A., Niemi M., Neuvonen P. J., Backman J. T., Trimethoprim and the CYP2C8i3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metabolism and Disposition 2008 36 1 73 80 2-s2.0-37549040583 10.1124/dmd.107.018010
-
(2008)
Drug Metabolism and Disposition
, vol.36
, Issue.1
, pp. 73-80
-
-
Tornio, A.1
Niemi, M.2
Neuvonen, P.J.3
Backman, J.T.4
-
64
-
-
79952837092
-
Discovery of a novel allelic variant of CYP2C8, CYP2C8i11, in asian populations and its clinical effect on the rosiglitazone disposition in vivo
-
2-s2.0-79952837092 10.1124/dmd.110.035899
-
Yeo C.-W., Lee S.-J., Lee S. S., Bae S. K., Kim E.-Y., Shon J.-H., Rhee B. D., Shin J.-G., Discovery of a novel allelic variant of CYP2C8, CYP2C8i11, in asian populations and its clinical effect on the rosiglitazone disposition in vivo. Drug Metabolism and Disposition 2011 39 4 711 716 2-s2.0-79952837092 10.1124/dmd.110.035899
-
(2011)
Drug Metabolism and Disposition
, vol.39
, Issue.4
, pp. 711-716
-
-
Yeo, C.-W.1
Lee, S.-J.2
Lee, S.S.3
Bae, S.K.4
Kim, E.-Y.5
Shon, J.-H.6
Rhee, B.D.7
Shin, J.-G.8
-
65
-
-
84874945128
-
The role of genetic variants in CYP2C8, LPIN1, PPARGCA and PPAR γ on the trough steady state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes
-
Stage T. B., Christensen M. M. H., Federsen S., Beck-Nielsen H., Brøsen K., The role of genetic variants in CYP2C8, LPIN1, PPARGCA and PPAR γ on the trough steady state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenetics and Genomics 2013 22 4 219 227
-
(2013)
Pharmacogenetics and Genomics
, vol.22
, Issue.4
, pp. 219-227
-
-
Stage, T.B.1
Christensen, M.M.H.2
Federsen, S.3
Beck-Nielsen, H.4
Brøsen, K.5
-
66
-
-
0345164399
-
Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: Identification of a Pro12Ala PPARγ2 missense mutation
-
DOI 10.1006/bbrc.1997.7798
-
Chung-Jen Y., Beamer B. A., Negri C., Silver K., Brown K. A., Yarnall D. P., Burns D. K., Roth J., Shuldiner A. R., Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPAR γ) gene in diabetic Caucasians: identification of a Pro12Ala PPAR γ 2 missense mutation. Biochemical and Biophysical Research Communications 1997 241 2 270 274 2-s2.0-0345164399 10.1006/bbrc.1997.7798 (Pubitemid 28020091)
-
(1997)
Biochemical and Biophysical Research Communications
, vol.241
, Issue.2
, pp. 270-274
-
-
Chung-Jen, Y.1
Beamer, B.A.2
Negri, C.3
Silver, K.4
Brown, K.A.5
Yarnall, D.P.6
Burns, D.K.7
Roth, J.8
Shuldiner, A.R.9
-
67
-
-
77949397703
-
The association between the peroxisome proliferator-activated receptor- γ 2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: A HuGE review and meta-analysis
-
2-s2.0-77949397703 10.1093/aje/kwp450
-
Gouda H. N., Sagoo G. S., Harding A.-H., Yates J., Sandhu M. S., Higgins J. P. T., The association between the peroxisome proliferator-activated receptor- γ 2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. American Journal of Epidemiology 2010 171 6 645 655 2-s2.0-77949397703 10.1093/aje/kwp450
-
(2010)
American Journal of Epidemiology
, vol.171
, Issue.6
, pp. 645-655
-
-
Gouda, H.N.1
Sagoo, G.S.2
Harding, A.-H.3
Yates, J.4
Sandhu, M.S.5
Higgins, J.P.T.6
-
68
-
-
77955481012
-
Common polymorphisms of the peroxisome proliferator-activated receptor- γ (Pro12Ala) and peroxisome proliferator-activated receptor- γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus
-
2-s2.0-77955481012 10.1016/j.metabol.2009.10.030
-
Hsieh M.-C., Lin K.-D., Tien K.-J., Tu S.-T., Hsiao J.-Y., Chang S.-J., Lin S.-R., Shing S.-J., Chen H.-C., Common polymorphisms of the peroxisome proliferator-activated receptor- γ (Pro12Ala) and peroxisome proliferator-activated receptor- γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism 2010 59 8 1139 1144 2-s2.0-77955481012 10.1016/j.metabol.2009.10.030
-
(2010)
Metabolism
, vol.59
, Issue.8
, pp. 1139-1144
-
-
Hsieh, M.-C.1
Lin, K.-D.2
Tien, K.-J.3
Tu, S.-T.4
Hsiao, J.-Y.5
Chang, S.-J.6
Lin, S.-R.7
Shing, S.-J.8
Chen, H.-C.9
-
69
-
-
23444457610
-
Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ2 gene on rosiglitazone response in type 2 diabetes
-
DOI 10.1016/j.clpt.2005.04.013, PII S0009923605001864
-
Kang E. S., Park S. Y., Kim H. J., Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor γ 2 gene on rosiglitazone response in type 2 diabetes. Clinical Pharmacology and Therapeutics 2005 78 2 202 208 2-s2.0-23444457610 10.1016/j.clpt.2005.04.013 (Pubitemid 41112288)
-
(2005)
Clinical Pharmacology and Therapeutics
, vol.78
, Issue.2
, pp. 202-208
-
-
Eun, S.K.1
So, Y.P.2
Hyeong, J.K.3
Chul, S.K.4
Chul, W.A.5
Bong, S.C.6
Sung, K.L.7
Chung, M.N.8
Hyun, C.L.9
-
70
-
-
34147106645
-
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone
-
DOI 10.1210/jc.2006-2275
-
Florez J. C., Jablonski K. A., Sun M. W., Bayley N., Kahn S. E., Shamoon H., Hamman R. F., Knowler W. C., Nathan D. M., Altshuler D., Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. Journal of Clinical Endocrinology and Metabolism 2007 92 4 1502 1509 2-s2.0-34147106645 10.1210/jc.2006-2275 (Pubitemid 46556431)
-
(2007)
Journal of Clinical Endocrinology and Metabolism
, vol.92
, Issue.4
, pp. 1502-1509
-
-
Florez, J.C.1
Jablonski, K.A.2
Sun, M.W.3
Bayley, N.4
Kahn, S.E.5
Shamoon, H.6
Hamman, R.F.7
Knowler, W.C.8
Nathan, D.M.9
Altshuler, D.10
-
71
-
-
18344417084
-
Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes
-
DOI 10.2337/diacare.26.3.825
-
Blüher M., Lübben G., Paschke R., Analysis of the relationship between the Pro12Ala variant in the PPAR- γ 2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003 26 3 825 831 2-s2.0-18344417084 10.2337/diacare.26.3.825 (Pubitemid 36929350)
-
(2003)
Diabetes Care
, vol.26
, Issue.3
, pp. 825-831
-
-
Bluher, M.1
Lubben, G.2
Paschke, R.3
-
72
-
-
80455160172
-
Polymorphism of peroxisome proliferator-activated receptor γ (PPAR γ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes
-
2-s2.0-80455160172 10.1016/j.ejphar.2011.09.158
-
Namvaran F., Azarpira N., Rahimi-Moghaddam P., Dabbaghmanesh M. H., Polymorphism of peroxisome proliferator-activated receptor γ (PPAR γ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. European Journal of Pharmacology 2011 671 1-3 1 6 2-s2.0-80455160172 10.1016/j.ejphar.2011.09. 158
-
(2011)
European Journal of Pharmacology
, vol.671
, Issue.1-3
, pp. 1-6
-
-
Namvaran, F.1
Azarpira, N.2
Rahimi-Moghaddam, P.3
Dabbaghmanesh, M.H.4
-
73
-
-
18144431682
-
The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes
-
DOI 10.2337/diacare.28.5.1139
-
Eun S. K., So Y. P., Hyeong J. K., Chul W. A., Nam M., Bong S. C., Sung K. L., Kyung R. K., Hyun C. L., The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005 28 5 1139 1144 2-s2.0-18144431682 10.2337/diacare.28.5.1139 (Pubitemid 40616625)
-
(2005)
Diabetes Care
, vol.28
, Issue.5
, pp. 1139-1144
-
-
Eun, S.K.1
So, Y.P.2
Hyeong, J.K.3
Chul, W.A.4
Nam, M.5
Bong, S.C.6
Sung, K.L.7
Kyung, R.K.8
Hyun, C.L.9
-
74
-
-
50249133701
-
The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes
-
2-s2.0-50249133701 10.1111/j.1463-1326.2008.00905.x
-
Li Z., Peng X., Wu Y., Xia Y., Liu X., Zhang Q., The influence of adiponectin gene polymorphism on the pioglitazone response in the Chinese with type 2 diabetes. Diabetes, Obesity and Metabolism 2008 10 9 794 802 2-s2.0-50249133701 10.1111/j.1463-1326.2008.00905.x
-
(2008)
Diabetes, Obesity and Metabolism
, vol.10
, Issue.9
, pp. 794-802
-
-
Li, Z.1
Peng, X.2
Wu, Y.3
Xia, Y.4
Liu, X.5
Zhang, Q.6
-
75
-
-
84863766951
-
Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus
-
2-s2.0-83655181377 10.1007/s11033-011-1354-5
-
Namvaran F., Rahimi-Moghaddam P., Azarpira N., Dabbaghmanesh M. H., Polymorphism of adiponectin (45T/G) and adiponectin receptor-2 (795G/A) in an Iranian population: relation with insulin resistance and response to treatment with pioglitazone in patients with type 2 diabetes mellitus. Molecular Biology Reports 2012 39 5 5511 5518 2-s2.0-83655181377 10.1007/s11033-011-1354-5
-
(2012)
Molecular Biology Reports
, vol.39
, Issue.5
, pp. 5511-5518
-
-
Namvaran, F.1
Rahimi-Moghaddam, P.2
Azarpira, N.3
Dabbaghmanesh, M.H.4
-
76
-
-
33846006173
-
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
-
DOI 10.1016/S0140-6736(06)69705-5, PII S0140673606697055
-
Drucker D. J., Nauck M. A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 2006 368 9548 1696 1705 2-s2.0-33846006173 10.1016/S0140-6736(06)69705-5 (Pubitemid 46048557)
-
(2006)
Lancet
, vol.368
, Issue.9548
, pp. 1696-1705
-
-
Drucker, D.J.1
Nauck, M.A.2
-
77
-
-
78650890818
-
Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: A pilot study
-
2-s2.0-78650890818 10.2337/dc10-0200
-
Sathananthan A., Dalla Man C., Micheletto F., Zinsmeister A. R., Camilleri M., Giesler P. D., Laugen J. M., Toffolo G., Rizza R. A., Cobelli C., Vella A., Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study. Diabetes Care 2010 33 9 2074 2076 2-s2.0-78650890818 10.2337/dc10-0200
-
(2010)
Diabetes Care
, vol.33
, Issue.9
, pp. 2074-2076
-
-
Sathananthan, A.1
Dalla Man, C.2
Micheletto, F.3
Zinsmeister, A.R.4
Camilleri, M.5
Giesler, P.D.6
Laugen, J.M.7
Toffolo, G.8
Rizza, R.A.9
Cobelli, C.10
Vella, A.11
-
78
-
-
75749091912
-
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
-
Saxena R., Hivert M. F., Langenberg C., Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nature Genetics 2010 42 2 142 148
-
(2010)
Nature Genetics
, vol.42
, Issue.2
, pp. 142-148
-
-
Saxena, R.1
Hivert, M.F.2
Langenberg, C.3
-
79
-
-
35848942800
-
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms
-
DOI 10.1007/s00125-007-0753-6
-
Schäfer S. A., Tschritter O., Machicao F., Thamer C., Stefan N., Gallwitz B., Holst J. J., Dekker J. M., T'Hart L. M., Nijpels G., Van Haeften T. W., Häring H. U., Fritsche A., Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia 2007 50 12 2443 2450 2-s2.0-35848942800 10.1007/s00125-007-0753-6 (Pubitemid 350060632)
-
(2007)
Diabetologia
, vol.50
, Issue.12
, pp. 2443-2450
-
-
Schafer, S.A.1
Tschritter, O.2
Machicao, F.3
Thamer, C.4
Stefan, N.5
Gallwitz, B.6
Holst, J.J.7
Dekker, J.M.8
T'Hart, L.M.9
Nijpels, G.10
Van Haeften, T.W.11
Haring, H.U.12
Fritsche, A.13
-
80
-
-
84871179193
-
Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7904146 risk T allele
-
Færch K., Pilgaard K., Knop F. K., Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7904146 risk T allele. Diabetes, Obesity and Metabolism 2013 15 1 91 95
-
(2013)
Diabetes, Obesity and Metabolism
, vol.15
, Issue.1
, pp. 91-95
-
-
Færch, K.1
Pilgaard, K.2
Knop, F.K.3
-
81
-
-
77449099615
-
TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action
-
2-s2.0-77449099615 10.2337/db09-1169
-
Villareal D. T., Robertson H., Bell G. I., Patterson B. W., Tran H., Wice B., Polonsky K. S., TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. Diabetes 2010 59 2 479 485 2-s2.0-77449099615 10.2337/db09-1169
-
(2010)
Diabetes
, vol.59
, Issue.2
, pp. 479-485
-
-
Villareal, D.T.1
Robertson, H.2
Bell, G.I.3
Patterson, B.W.4
Tran, H.5
Wice, B.6
Polonsky, K.S.7
-
82
-
-
67650251656
-
Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion
-
2-s2.0-67650251656 10.2337/db08-1589
-
Müssig K., Staiger H., Machicao F., Kirchhoff K., Guthoff M., Schäfer S. A., Kantartzis K., Silbernagel G., Stefan N., Holst J. J., Gallwitz B., Häring H.-U., Fritsche A., Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes 2009 58 7 1715 1720 2-s2.0-67650251656 10.2337/db08-1589
-
(2009)
Diabetes
, vol.58
, Issue.7
, pp. 1715-1720
-
-
Müssig, K.1
Staiger, H.2
Machicao, F.3
Kirchhoff, K.4
Guthoff, M.5
Schäfer, S.A.6
Kantartzis, K.7
Silbernagel, G.8
Stefan, N.9
Holst, J.J.10
Gallwitz, B.11
Häring, H.-U.12
Fritsche, A.13
-
83
-
-
67349190497
-
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion
-
2-s2.0-67349190497 10.1007/s00125-009-1344-5
-
Schäfer S. A., Müssig K., Staiger H., MacHicao F., Stefan N., Gallwitz B., Häring H. U., Fritsche A., A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia 2009 52 6 1075 1082 2-s2.0-67349190497 10.1007/s00125-009-1344-5
-
(2009)
Diabetologia
, vol.52
, Issue.6
, pp. 1075-1082
-
-
Schäfer, S.A.1
Müssig, K.2
Staiger, H.3
Machicao, F.4
Stefan, N.5
Gallwitz, B.6
Häring, H.U.7
Fritsche, A.8
-
84
-
-
84860588948
-
Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1
-
2-s2.0-84860588948 10.2337/db11-1732
-
Smushkin G., Sathananthan M., Sathananthan A., Man C. D., Micheletto F., Zinsmeister A. R., Cobelli C., Vella A., Diabetes-associated common genetic variation and its association with GLP-1 concentrations and response to exogenous GLP-1. Diabetes 2012 61 5 1082 1089 2-s2.0-84860588948 10.2337/db11-1732
-
(2012)
Diabetes
, vol.61
, Issue.5
, pp. 1082-1089
-
-
Smushkin, G.1
Sathananthan, M.2
Sathananthan, A.3
Man, C.D.4
Micheletto, F.5
Zinsmeister, A.R.6
Cobelli, C.7
Vella, A.8
-
85
-
-
84885215197
-
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway
-
't Haart L. M., Fritsche A., Nijpels G., The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes 2013 62 9 3275 3281
-
(2013)
Diabetes
, vol.62
, Issue.9
, pp. 3275-3281
-
-
'T Haart, L.M.1
Fritsche, A.2
Nijpels, G.3
-
86
-
-
84858798082
-
Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing
-
2-s2.0-84858798082 10.1038/clpt.2011.355
-
Martin M. A., Klein T. E., Dong B. J., Pirmohamed M., Haas D. W., Kroetz D. L., Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clinical Pharmacology and Therapeutics 2012 91 4 734 738 2-s2.0-84858798082 10.1038/clpt.2011.355
-
(2012)
Clinical Pharmacology and Therapeutics
, vol.91
, Issue.4
, pp. 734-738
-
-
Martin, M.A.1
Klein, T.E.2
Dong, B.J.3
Pirmohamed, M.4
Haas, D.W.5
Kroetz, D.L.6
|